Farhad Ravandi

This study identifies BRAF mutations in AML, showing poor outcomes and unique co-mutation patterns, suggesting potential targeted therapies.

This study shows that resistant clones are rapidly selected in hematopoietic cell compartments with leukemic stem cell potential before relapse in patients treated with ivosidenib combination therapy.

This study examines how chemotherapy affects clonal diversity and mutation patterns in hematopoietic stem cells, finding that melphalan increases mutational burden and promotes clonal aging, potentially leading to therapy-related myeloid neoplasms.

The paper quantifies the impact of TP53 mutations in myelodysplastic syndromes using an evolutionary action score and correlates it with clinical and genomic features, finding that low-EAp53 mutations are associated with better survival.